Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 15;217(4):e20190179. doi: 10.1084/jem.20190179

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Capietto et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 3. — Cross-reactivity between MHC-I mutant and WT counterpart neoantigens. (A–G) Representative data of mean ± SD IFN-gamma spot numbers from CD8 T cells (5 × 10⁵ CD4-depleted splenocytes/well) from control mice (Ctr., n = 1) or mice immunized with mutant SLPs (Im., n = 3) as depicted in Fig. 1 B, after in vitro restimulation with the mutant SLP or its WT counterpart (25 µg/ml; A-M44 mutation, MC-38; B-C154 mutation, CT-26; C-E22 mutation, EMT-6; D-M10 mutation, MC-38; E-M86 mutation, MC-38; F-M134 mutation, MC38; and G-M7 mutation, MC-38) or with the predicted mutant optimal epitope SSP or its WT counterpart (C, D, and G). Binding assay of the optimal mutant and its WT counterpart SSPs to H-2Kb on Tap-1 KO EL-4 cells is shown, as well as the sequence and the BA (percentile rank) of the predicted optimal epitopes (E–G). Each experiment was performed twice independently.